Separate active inflammation from permanent damage and complications. Choose the imaging that can answer the next clinical question; a bright or dark lesion alone is not a diagnosis.
Terminology and draft status
Selected imaging terms were checked in the WHO UMD. Further medical terms remain working translations pending terminology and specialist review. Original terms and open source questions are retained; source, translation and medical approval remain pending.
01Start with the question and a comparable fundus record
Imaging documents the baseline, detects clinically hidden findings, quantifies structural damage and supports treatment and prognosis. First identify the site of inflammation, suspected cause and threat to vision. Infection and masquerade disease remain part of the differential; imaging supports rather than replaces the clinical assessment. 8 14
Multimodal imaging combines complementary information. Ask whether the immediate problem is retinal leakage, choroidal involvement, macular structure, a vascular network or an obscured fundus. Availability and cost matter; neither every modality nor wide-field angiography is compulsory for every patient. 4 8 14
Colour fundus photography records the appearance and location of lesions and helps patients understand change. Compare images before, during and after treatment. A fluffy, poorly defined lesion becoming a dry, pigmented scar is an illustrative course; colour appearance alone does not establish activity or its cause. 1 2 3
Wide-field systems, including Optos, can document peripheral disease. When unavailable, directional images and montage or sweeps can cover central, superior, inferior, nasal and temporal regions. Compare field, gaze, illumination, magnification and distortion before interpreting apparent progression. 8
Red-free imaging uses filtered light to emphasise structures such as the retinal nerve-fibre layer and optic disc. It is not autofluorescence or dye angiography. Check the actual device mode; acquisition settings and device-specific performance still require the corresponding technical source. 8
02Read autofluorescence in its disease context
Fundus autofluorescence (FAF) records intrinsic fluorescence without injected dye. Short-wavelength FAF is strongly influenced by lipofuscin-related signal in the retinal pigment epithelium (RPE), but it is not a direct measurement of RPE cell health or metabolism. Other fluorophores, blocking material and acquisition artifacts alter the image. 1 2 8 15
Hyperautofluorescence means a brighter signal; hypoautofluorescence means a darker signal. Brightness can accompany active injury but is not specific for inflammation. Darkness can reflect RPE loss or scarring, but also signal blockage; it does not invariably mean dead cells. 1 2 15
In serpiginous choroiditis, compare the advancing border with older scars and serial images. The original illustration describes a 60-year-old patient whose bright border later became dark after healing; it is a teaching example, not an independently verified case. Exclude infectious serpiginous-like mimics when clinically relevant. 1 8 15
Birdshot may show hypoautofluorescent damage. In multiple evanescent white dot syndrome (MEWDS), FAF can reveal changes missed on colour photographs and residual changes after clinical recovery. Vogt–Koyanagi–Harada (VKH) disease can show altered FAF with serous detachment; diffuse brightness alone does not prove lipofuscin accumulation or active disease. 1 3 8 15
For multifocal choroiditis with panuveitis (MFCPU) and punctate inner choroiditis (PIC), the MUV5 expert consensus favours structural OCT for activity assessment. A bright FAF cuff can persist around an inactive lesion, scar, fluid or associated choroidal neovascularisation. Do not escalate treatment from that rim alone. 2
The MUV reports are disease-specific expert consensus based on selected cases and literature. MUV8 involved five specialists and 15 representative birdshot cases; it reached no consensus on the role of FAF or OCTA. That is not proof that either method is useless, and expert agreement is not diagnostic sensitivity. 2 3
03Use fluorescein angiography to assess leakage and perfusion
Fluorescein angiography (FA, also called FFA) photographs intravenously administered fluorescein through successive prearterial, arterial, arteriovenous and late phases. It is a reference method for retinal vascular leakage. The original late-phase example of about 6 minutes is approximate; the clinical question and local protocol determine acquisition. 7 8
Inspect arterial and venous involvement, capillary filling, late leakage or staining, optic-disc fluorescence and abnormal new vessels. Arteritis can occur with lupus and phlebitis with sarcoidosis or Behçet disease, but these associations do not establish aetiology. Late vascular staining without early leakage can also represent vasculopathy rather than active vasculitis. 8
Disc leakage may accompany optic-disc inflammation, but angiographic brightness alone does not establish clinical papillitis. Petaloid accumulation supports cystoid macular oedema (CME); nonfilling raises concern for nonperfusion after excluding blockage and technical failure. Leaky new vessels require assessment of the underlying ischaemic or inflammatory process. 8 14
In Behçet disease, peripheral fern-like leakage and occlusive vasculitis can be more extensive than the visible clinical findings. Ischaemia may lead to neovascularisation and vitreous haemorrhage. Peripheral wide-field or montage images are useful when that question is relevant, rather than mandatory for every uveitis phenotype. 8
White-dot disorders, birdshot and serpiginous choroiditis can show early hypofluorescence and late staining, with disease-specific variation. VKH can show multiple pinpoint leaks, pooling and disc leakage, described as a starry-night pattern. Interpret phase and distribution with the full multimodal picture; one named pattern does not establish the diagnosis. 1 3 8
FA provides less direct access to the choroid because overlying tissues and the dye signal affect visibility. Before injection, check the actual product, previous reactions, relevant illness, medications including beta-blockers, pregnancy or breastfeeding and emergency arrangements. Severe reactions can occur; follow the applicable product information and local protocol, not a generic dose or emergency regimen. 7 9 10
04Add ICGA when the choroid is the question
Indocyanine green angiography (ICGA) uses injected ICG, extensive protein binding and near-infrared imaging to assess the choroidal circulation. Mid and late images, sometimes beyond 15 minutes in the original teaching, can add information; the timing depends on the question and protocol. 2 3 8 9
Typical questions include birdshot, VKH, sympathetic ophthalmia, serpiginous or other white-dot disease and suspected tuberculous choroidal lesions. Choroidal vascularity does not prove tuberculosis, and the original oxygen-rich-choroid explanation is not a validated diagnostic mechanism. Investigate infection from the whole clinical picture. 1 3 8
In birdshot, ICGA may reveal lesions when colour photography or FA is less revealing. HLA-A29 supports the appropriate phenotype but is not a diagnosis by itself. SUN research classification used selected posterior-uveitis cases, not an unselected clinic population; its classification performance cannot be treated as the accuracy of ICGA alone. 3 5
Dark choroidal spots can reflect altered perfusion, tissue involvement or other signal effects, depending on the disease and phase. MUV5 did not identify reliable ICGA biomarkers separating active from inactive MFCPU/PIC. A dark optic disc versus a brighter FA disc is an orientation clue, not a validated way to identify every image: confirm the modality and acquisition metadata. 2 8
Behçet disease primarily raises retinal vascular questions, so FA is often more useful. Lack of a usual indication for ICGA is different from a pharmacological contraindication. A separate choroidal question can still justify ICGA after individual assessment. 8 9 10
The inspected UK Zyogreen and US IC-GREEN labels differ in their listed contraindications and precautions. Previous ICG hypersensitivity and anaphylaxis preparedness matter; thyroid, iodine-related and pregnancy or breastfeeding provisions must be checked against the actual formulation and jurisdiction. Neither label establishes a general Behçet contraindication; a UK or US label is not German prescribing authority. 9 10
05Use structural OCT to measure tissue and explain vision
Optical coherence tomography (OCT) creates high-resolution optical cross-sections, sometimes called an optical biopsy. It measures thickness and shows intraretinal or subretinal fluid, the vitreomacular interface and retinal microstructure. It does not provide histology or identify the infectious agent. 8 14
For macular oedema, compare fluid, thickness maps and the actual B-scans using comparable devices and segmentation. The original decrease from 635 µm to 400 µm illustrates anatomical response; it is not a verified trial effect or a promise of improved vision. Hyperreflective dots are descriptive findings, not a specific identification of inflammatory cells. 6 8
Macular complications can accompany anterior uveitis, especially when vision is reduced or the course raises concern. The original claim of up to 50% subclinical oedema lacks a verified population, denominator and definition. It cannot justify a universal prevalence estimate or mandatory OCT for every anterior-uveitis visit. 14
Ellipsoid-zone (EZ) disruption can indicate photoreceptor injury and help explain limited vision after oedema resolves. It is not universally the strongest predictor or proof of irreversible loss. In the inspected retrospective series of 84 eyes from 66 patients selected for oedema resolution, EZ disruption was associated with final vision in univariable analysis, while baseline central thickness remained in the reported multivariable model. 6
That selected, heterogeneously treated cohort cannot establish causation or a universal prognostic ranking. Eyes from the same person, image-quality exclusions and selection after anatomical response affect interpretation. The actual model coefficients and confidence intervals were not inspected; do not infer a validated decision threshold. 6
OCT localises retinal, RPE and choroidal involvement. A choroidal tuberculous granuloma can elevate overlying tissue; toxoplasma retinochoroiditis can involve the full retina and adjacent choroid. The original below-versus-above illustration must not become an exclusive layer rule or a definitive aetiological test. 8
Enhanced-depth imaging OCT (EDI-OCT) improves assessment of deeper choroidal structure in selected settings, including VKH or sympathetic ophthalmia. Compare choroidal thickness and fluid with disease phase and acquisition conditions; neither thickness nor any single section establishes activity independently. 8
06Separate a flow image from leakage and active neovascularisation
OCT angiography (OCTA) uses repeated optical scans to detect motion contrast from blood cells without injected dye. It can map retinal or choriocapillaris flow deficits and detect a choroidal neovascularisation (CNV) network, including around an old toxoplasma scar. These findings support assessment but do not by themselves prove activity. 2 8
OCTA does not display leakage and cannot replace FA for that question in vasculitis. An apparent flow deficit can reflect true nonperfusion, slow flow below detection, shadowing, poor segmentation, motion or projection artifacts. Review structural B-scans and en face images before calling tissue ischaemic. 2 8
Media opacity, poor fixation, restricted field and device or acquisition differences can hide lesions or imitate change. A negative OCTA study does not reliably exclude a network outside the scanned or adequately imaged region; MUV8 reached no consensus on routine OCTA roles in birdshot. 3 8
07Image behind opaque media and inspect the ciliary body
B-scan ultrasonography provides a two-dimensional acoustic view when dense vitritis, cataract or a small synechial pupil prevents adequate fundus assessment. It can reveal vitreous echoes, retinal detachment, posterior-wall changes or a mass. Echoes are not a direct measure of inflammatory activity, and detachment type may require additional examination. 8 14
Posterior sclerochoroidal thickening and fluid in the sub-Tenon region around the optic nerve may produce a T-sign supporting posterior scleritis. Its absence does not exclude the condition. Other causes of pain, detachment or posterior-wall change still need assessment. 11
A retrospective series of nine mild unilateral cases found a T-sign in only one eye. A 1.7 mm cut-off yielded 87.5% sensitivity and 88.9% specificity in that selected sample. Small size and ultrasound-informed diagnosis limit generalisation; this is not an independently validated universal threshold. 11
Ultrasound biomicroscopy (UBM) uses higher frequencies for detailed iris, ciliary-body, angle and peripheral anterior-vitreous imaging, trading penetration for resolution. It can help assess cyclitic or pars plana membranes, traction, ciliary detachment and hypotony, including intermediate uveitis, when the relevant anatomy is poorly accessible clinically. 12 13
In a retrospective series of 36 eyes from 25 patients with uveitic hypotony, UBM guided selected medical or surgical management; 66.7% of eyes had improved intraocular pressure. Without a randomised comparator, this does not prove that UBM itself improves pressure or vision. A 2026 three-case report adds illustrations, not diagnostic-accuracy or treatment-effect estimates. 12 13
08Combine the findings before changing treatment
Use the summary table as a question-led guide. Confirm the modality, phase, field, image quality and serial comparability; distinguish new inflammatory activity from residual scars, oedema, traction, ischaemia and CNV. Unexpected or discordant findings require reassessment rather than automatic treatment escalation. 1 2 3 8
MUV9 tested imaging interpretation in 156 ophthalmologists using selected noninfectious posterior-uveitis examples from six entities. Its minimum-image-set results are about diagnostic interpretation; performance above 75% was confined to classic cases. This is neither a patient-randomised vision-benefit trial nor a requirement to order every modality. 4
The original lecture link is retained for provenance; its recording, slides and Rola Al-Hamam attribution have not been independently verified. Exact source-access and terminology limits are documented separately. Drug safety follows current local product information; clinically urgent assessment must not wait for imaging availability. 7 9 10
| Modality | Principle | Main clinical questions | Findings and patterns | Limits and next check |
|---|---|---|---|---|
| Colour fundus photography | Photographic record of the fundus. | Baseline documentation, serial and treatment comparison, patient explanation. | Lesion morphology: fluffy or poorly defined appearance versus pigmented scar. | Wide-field or directional montage when the peripheral question requires it; appearance alone does not prove activity. |
| Fundus autofluorescence (FAF) | Intrinsic fluorescence, influenced by RPE lipofuscin and other signal sources. | Disease-specific lesion and recurrence assessment; white-dot and serpiginous disease. | Bright rims may accompany activity or persist in inactive lesions; darkness may reflect atrophy, scar or blockage. | Signal maps are not a direct cell-function measurement; compare OCT and serial clinical findings. |
| Fluorescein angiography (FA/FFA) | Intravenous fluorescein and phased retinal vascular imaging. | Retinal vasculitis, macular leakage, ischaemia and neovascularisation. | Vascular or disc leakage; petaloid CME; fern-like Behçet leakage; VKH pinpoint or starry-night pattern. | Invasive; peripheral wide-field or montage images are indication-led, not obligatory for all uveitis. |
| Indocyanine green angiography (ICGA) | Injected protein-bound ICG with near-infrared choroidal imaging. | Choroidal questions in birdshot, VKH and suspected tuberculous or other choroiditis. | Dark spots may show lesions but do not universally distinguish activity from inactivity. | Often dark disc is an orientation clue; complements FA, not a replacement; check dye safety separately. |
| Optical coherence tomography (OCT) | Noninvasive optical cross-sections and tissue measurements. | Macular oedema monitoring, vitreomacular interface and context-specific prognosis. | EZ disruption, retinal versus choroidal involvement and hyperreflective dots require clinical interpretation. | Useful when indicated, including anterior uveitis; anatomy and thickness do not guarantee visual outcome. |
| OCT angiography (OCTA) | Noninvasive detection of flow-related motion contrast. | Assessment of flow deficits or ischaemia and CNV networks. | Reduced or absent detectable flow and vascular networks; artifacts and slow flow can mislead. | No leakage information; does not replace FA for leakage/activity questions. |
| Ultrasound: B-scan / UBM | Acoustic imaging; posterior B-scan versus higher-frequency anterior UBM. | Obscured fundus and suspected posterior scleritis; selected ciliary-body or membrane questions. | T-sign, vitreous echoes or retinal detachment; UBM can show traction, membranes and ciliary detachment. | Useful when direct assessment is inadequate; no universal detachment or scleritis rule from a single image. |
What are the main learning points of this lecture?
Choose imaging for the suspected site and clinical question. Separate inflammation from damage and complications, combine complementary techniques and compare reliable serial images. Do not turn one signal pattern or a selected study into a universal diagnostic or treatment rule.
Which findings need urgent assessment?
Sudden or worsening vision loss, a new field defect, severe eye pain or marked inflammation need prompt assessment. Pressure-related symptoms and suspected infection or neurological disease require appropriate urgent escalation; imaging should support rather than delay that care.
References and access status
- 1MUV4 · Serpiginous imaging · 2025
Complete indexed abstract read; selected-case expert consensus, not prospective diagnostic accuracy. Main paper, figures and underlying studies unread.
- 2MUV5 · MFCPU/PIC imaging · 2025
Main text pp272–282 and selected actual images pp277/278/281 read. Not all figures, appendix, supplements or underlying cited studies; disease-specific expert consensus.
- 3MUV8 · Birdshot imaging · 2025
Complete indexed abstract read; five specialists/15selected cases. Full paper and images not obtained; download response was HTML.
- 4MUV9 · Minimum imaging sets · 2025
Complete indexed abstract read; interpretation exercise in156ophthalmologists. Full tables, effect estimates, paired analysis and selected image sets unread.
- 5SUN · Birdshot classification · 2021
Complete indexed abstract read. Selected research classification; full criteria table, images and supplements unread.
- 6Bodur et al. · OCT prognosis · 2026
Selected actual main-text sections read. Retrospective84eyes/66patients; actual coefficients, confidence intervals and figure images not inspected.
- 7Fluorescein sodium100mg/ml · UK SmPC
Selected sections4.1–4.6read; product- and jurisdiction-specific, not the whole label or German prescribing authority.
- 8AAO · Uveitis Subspecialty Day2024 · Imaging in posterior uveitis
Actual text of the imaging section,printedpp28–29read. Educational syllabus, not a formal PPP or systematic guideline; other chapters and cited full reports not appraised here; selected imaging text on p42 also read
- 9Zyogreen · UK SmPC · 25September2026
Actual selected sections4.1–4.6read. Product-specific warnings and contraindications; not a general protocol or German authorisation. Selected sections5.1–5.2on optical properties and protein binding also read.
- 10IC-GREEN · US prescribing information · January2026
Actual selected indications,ophthalmic section,contraindications,warnings and pregnancy/lactation text read; no imported dose or emergency regimen.
- 11Maleki et al. · Posterior scleritis · 2022
Actual main text and table text read; figure images and underlying reports not inspected. Nine selected mild unilateral cases; ultrasound contributed to diagnosis.
- 12Ganesh et al. · UBM in uveitic hypotony · 2022
Complete indexed abstract read; retrospective36eyes/25patients with selected treatment. Full report,images,protocol and uncertainty estimates unread.
- 13El Hachimi et al. · UBM case report · 2026
Complete indexed abstract and captions read; three-case illustration. Main report,actual images and prognosis definitions not independently appraised.
- 14DOG/BVA24a · Intermediate uveitis · 14June2020
Actual selected diagnostic text printedpp5–6read; historical disease-specific guidance, not a current universal imaging schedule. Other sections and methods not fully appraised here.
- 15Mauschitz et al. · FAF review/case series · 2024
Actual abstract,introduction,selected MEWDS/MCP sections and discussion text read. Narrative review/case series;not a prospective diagnostic-accuracy trial. Actual figure images and underlying cited reports not inspected.
Original lecture links
For patients
Different eye images answer different questions. Photographs record appearance, OCT shows tissue and fluid, and other tests assess leakage, blood flow or structures hidden from direct view. Your clinician chooses the useful combination with the examination.
A change on a scan does not always mean that inflammation is active, and reduced swelling does not guarantee full visual recovery. Previous damage and other complications may also affect vision; comparable follow-up images help explain the course.
Some tests need an injected dye. Tell the team about previous reactions, medicines, relevant illnesses and pregnancy or breastfeeding. These learning notes do not replace your individual examination or treatment plan.
Seek urgent medical assessment for sudden loss of vision, a new visual-field defect, severe pain, marked inflammation, pressure-related symptoms or suspected infection or neurological disease. Do not wait for a routine imaging appointment if symptoms are acute.